Floatz logo

Nivolumab

Stage III Anal Cancer AJCC v8

Instituto do Cancer do Estado de São Paulomonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Stage III Anal Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Federation Francophone de Cancerologie Digestive
Phase 3BB
Carboplatin
Dustin Deming
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
MITOMYCIN C
Federation Francophone de Cancerologie Digestive
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Federation Francophone de Cancerologie Digestive
Phase 3BB

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →